NASDAQ:PYXS Pyxis Oncology Q3 2026 Earnings Date & Estimates $2.03 +0.04 (+2.01%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.03 0.00 (0.00%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Pyxis Oncology is expected to report Q3 2026 earnings on Monday, November 2, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 9:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 2, 2026TimeBefore Market OpensConference Call DateNovember 6, 2026Conference Call9:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Pyxis Oncology in Q3 2026Pyxis Oncology is expected to post earnings of -$0.27 per share. In the same quarter a year earlier Pyxis Oncology reported -$0.35 per share. Pyxis Oncology last reported on August 13, 2026, posting -$0.40 per share and missing the -$0.35 consensus estimate. Pyxis Oncology has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.27Prior-Year EPS-$0.35Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.40 (Missed by -$0.05)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Pyxis Oncology Q3 2026 Earnings FAQ When does Pyxis Oncology report Q3 2026 earnings? Pyxis Oncology (NASDAQ:PYXS) is estimated to report Q3 2026 earnings on Monday, November 2, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Pyxis Oncology's Q3 2026 earnings call? Pyxis Oncology's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Pyxis Oncology? Analysts expect Pyxis Oncology to post earnings of -$0.27 per share for Q3 2026. Pyxis Oncology Earnings HeadlinesPyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&DOctober 4, 2026 | seekingalpha.comPyxis Oncology, Inc. (NASDAQ:PYXS) Stock Has Average Target Price of $8.75October 4, 2026 | americanbankingnews.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 10 at 1:00 AM | Weiss Ratings (Ad)Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Pyxis Oncology (PYXS)October 3, 2026 | theglobeandmail.comPyxis Oncology Closes $110 Million Public Offering to Advance MICVO Clinical DevelopmentOctober 2, 2026 | quiverquant.comQPyxis Oncology Announces Closing of Up to $282.6 Million Public OfferingOctober 2, 2026 | globenewswire.comSee More Pyxis Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pyxis Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pyxis Oncology and other key companies, straight to your email. Email Address About Pyxis OncologyPyxis Oncology (NASDAQ:PYXS) (NASDAQ: PYXS) is a clinical-stage biotechnology company developing therapies for cancer. The company focuses on treatments designed to address both tumor cells and the tumor microenvironment, with the goal of improving the effectiveness of the immune system and other anticancer mechanisms against solid tumors. Its research and development programs include antibody-drug conjugates and immunotherapies. Pyxis Oncology’s lead program, PYX-201, is an antibody-drug conjugate designed to target the extradomain B form of fibronectin, a protein found in the tumor microenvironment, and deliver an anticancer payload to tumor tissue. The company has also developed additional antibody-based programs intended to modulate immune responses or target features associated with cancer. Pyxis Oncology was founded in 2019 and is headquartered in Boston, Massachusetts. Its therapies are in clinical development, and the company’s programs are being evaluated in cancer indications with significant unmet medical needs. Lara Sullivan, M.D., is a co-founder and has served as the company’s president and chief executive officer.View Pyxis Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
